Cullinan Therapeutics earnings were -$222.4M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest CGEM earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$49.7M, down 2.1% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, CGEM reported annual earnings of -$220.6M, with 31.2% growth.
Cullinan Therapeutics Earnings Reports & History FAQ
What were Cullinan Therapeutics's earnings last quarter?
Cullinan Therapeutics (NASDAQ: CGEM) reported Q1 2026 earnings per share (EPS) of -$0.75, up 1.35% year over year. Total CGEM earnings for the quarter were -$49.66 million. In the same quarter last year, Cullinan Therapeutics's earnings per share (EPS) was -$0.74.
Is Cullinan Therapeutics profitable or losing money?
As of the last Cullinan Therapeutics earnings report, Cullinan Therapeutics is currently losing money. Cullinan Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$221.04 million, a 23.67% increase year over year.
What was CGEM's earnings growth in the past year?
As of Cullinan Therapeutics's earnings date in Q2 2026, Cullinan Therapeutics's earnings has grown year over year. CGEM earnings in the past year totalled -$222.36 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.